Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,571 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03358472 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | completed | Phase 3 | 89 | Incyte CorporationINDUSTRY | 14 | Sep 29, 2026 | clinicaltrials |
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | recruiting | Phase 3 | 158 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT06496178 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) | active not recruiting | Phase 3 | 621 | Merus B.V.INDUSTRY | 24 | Sep 25, 2026 | clinicaltrials |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | active not recruiting | Phase 3 | 699 | Merus B.V.INDUSTRY | 28 | Sep 25, 2026 | clinicaltrials |
| NCT07276399 | A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer(OrigAMI-5) | recruiting | Phase 3 | 500 | Janssen Research & Development, LLCINDUSTRY | 22 | Sep 25, 2026 | clinicaltrials |
| NCT06475989 | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | recruiting | Phase 3 | 264 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04534205 | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1(AHEAD-MERIT) | active not recruiting | Phase 2 / Phase 3 | 358 | BioNTech SEINDUSTRY | 21 | Sep 21, 2026 | clinicaltrials |
| NCT06258811 | Neoadjuvant Immunochemotherapy for LAOSCC | recruiting | Phase 3 | 134 | Lai-ping ZhongOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07827872 | Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 300 | caohaotianOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06629597 | A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) | active not recruiting | Phase 3 | 400 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07177443 | Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 710 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06641791 | Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer | recruiting | Phase 3 | 196 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07783321 | A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04255849 | Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV | active not recruiting | Phase 3 | 700 | Weill Medical College of Cornell UniversityOTHER | 3 | Sep 14, 2026 | clinicaltrials |
| NCT05721755 | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 3 | 290 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05187091 | The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas(SWOAR) | recruiting | Phase 3 | 136 | All India Institute of Medical SciencesOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02135042 | Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | active not recruiting | Phase 2 / Phase 3 | 924 | NRG OncologyOTHER | 8 | Sep 10, 2026 | clinicaltrials |
| NCT07026474 | Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC(RePaIr-HN) | recruiting | Phase 3 | 214 | Universität des SaarlandesOTHER | 2 | Sep 10, 2026 | clinicaltrials |
| NCT07813351 | PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours(PRESTO) | not yet recruiting | Phase 3 | 82 | University College, LondonOTHER | 0 | Sep 10, 2026 | clinicaltrials |
| NCT04590963 | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer(INTERLINK-1) | active not recruiting | Phase 3 | 370 | AstraZenecaINDUSTRY | 23 | Sep 9, 2026 | clinicaltrials |
| NCT05751512 | A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN | recruiting | Phase 3 | 180 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06129864 | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy(eVOLVE-HNSCC) | recruiting | Phase 3 | 1,145 | AstraZenecaINDUSTRY | 23 | Sep 3, 2026 | clinicaltrials |
| NCT07509099 | Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC | not yet recruiting | Phase 3 | 316 | Ji DongmeiOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(VERSATILE-003) | terminated | Phase 3 | 12 | PDS Biotechnology Corp.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT01520701 | Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy(IPAC) | completed | Phase 3 | 130 | Centre Francois BaclesseOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | suspended | Phase 2 / Phase 3 | 613 | National Cancer Institute (NCI)NIH | 3 | Sep 1, 2026 | clinicaltrials |
| NCT02997553 | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery(GASVERT) | completed | Phase 3 | 744 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer | suspended | Phase 3 | 420 | National Cancer Institute (NCI)NIH | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07796789 | Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 204 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06976190 | A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(Magic-C002) | recruiting | Phase 3 | 446 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07768189 | A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma(TEMPO-1) | not yet recruiting | Phase 3 | 260 | Corbus Pharmaceuticals Inc.INDUSTRY | 3 | Aug 31, 2026 | clinicaltrials |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 3 | 403 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT07791745 | A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 362 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03258554 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | completed | Phase 2 / Phase 3 | 196 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07201337 | Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. | active not recruiting | Phase 3 | 700 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04456322 | Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 381 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04178174 | Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer(SHORT-OPC) | recruiting | Phase 3 | 360 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT01893307 | Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer | active not recruiting | Phase 3 | 440 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06998069 | Head and Neck Cancer Study Project in the Geriatric Population | recruiting | Phase 3 | 20 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00162708 | Very Intense Radiotherapy-chemotherapy Regimen in Advanced HNSCC | completed | Phase 2 / Phase 3 | 120 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04333537 | Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | recruiting | Phase 2 / Phase 3 | 686 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07441681 | Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin | recruiting | Phase 3 | 454 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06712888 | Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma(Navigation) | active not recruiting | Phase 3 | 466 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05979961 | Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 464 | Sun Yat-sen UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05273307 | Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy | active not recruiting | Phase 3 | 40 | University of California, San FranciscoOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07758621 | SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC | not yet recruiting | Phase 3 | 340 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Aug 11, 2026 | clinicaltrials |
| NCT03765918 | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | active not recruiting | Phase 3 | 714 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Jul 31, 2026 | clinicaltrials |
| NCT04747054 | Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers(PembroMetaRT) | recruiting | Phase 3 | 102 | UNICANCEROTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05063552 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | active not recruiting | Phase 2 / Phase 3 | 430 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
Data updated 1 hour agoSource updated Sep 29, 2026source: clinicaltrials